Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Milestone Pharmaceuticals

Milestone Pharmaceuticals
2005 FOUNDED
IPO REG STATUS
21-30 EMPLOYEES
IPO LATEST DEAL TYPE (Announced)
$86.2M LATEST DEAL AMOUNT
14 INVESTORS
Description

Developer of novel small molecule therapeutics intended to provide rapid-onset and short-acting treatment of paroxysmal supraventricular tachycardia (PSVT) episodes and other episodic conditions. The company's therapeutics include a a potent and short-acting nasally-delivered calcium channel antagonist in development for the episodic treatment of paroxysmal supraventricular tachycardia, enabling physicians to treat transient cardiovascular conditions, resulting in a better medical outcome.

Ownership Status
In IPO Registration
Financing Status
Venture Capital-Backed
Primary Industry
Pharmaceuticals
Other Industries
Biotechnology
Drug Discovery
Primary Office
  • 1111 Dr.-Frederik-Philips Boulevard
  • Suite 420
  • Saint-Laurent, Quebec H4M 2X6
  • Canada

+1 (514) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Milestone Pharmaceuticals’s full profile, request a free trial.

Milestone Pharmaceuticals Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. IPO 12-Apr-2019 $86.2M 00000 Announced Clinical Trials - Phase 3
7. Later Stage VC 25-Oct-2018 0000 00000 Completed Clinical Trials - Phase 3
6. Later Stage VC (Series C) 01-Aug-2017 0000 000.00 Completed Clinical Trials - Phase 2
5. Later Stage VC (Series B) 15-Jun-2015 0000 000.00 Completed Clinical Trials - Phase 2
4. Later Stage VC (Series A2) 13-Jun-2011 0000 000.00 Completed Clinical Trials - General
3. Early Stage VC (Series A1) 01-Jan-2009 000 00.000 Completed Startup
2. Debt - General 31-May-2007 $393K $393K Completed Startup
1. Seed Round 01-Jun-2005 Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Milestone Pharmaceuticals Investors (14)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
BDC Capital Venture Capital Minority 000 0000 000000 0
RTW Investments Venture Capital Minority 000 0000 000000 0
Tavistock Group PE/Buyout Minority 000 0000 000000 0
Venrock Venture Capital Minority 000 0000 000000 0
Forbion Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 14 investors. Get the full list »

Milestone Pharmaceuticals Executive Team (10)

Name Title Board
Seat
Contact
Info
Joseph Oliveto Chief Executive Officer, President & Board Member
Philippe Douville Ph.D Chief Scientific Officer & Co-Founder
Lorenz Muller Chief Commercial Officer
Douglas Wight Vice President, Drug Development
Guy Rousseau Ph.D Vice President, Regulatory Affairs

3 Former Executives

You’re viewing 5 of 10 executives. Get the full list »

Milestone Pharmaceuticals Board Members (17)

Name Representing Role Since Contact
Info
Brian Dovey Domain Associates Board Observer 000 0000
Daniel Omstead Ph.D Tekla Capital Management Board Observer 000 0000
Debra Liebert Domain Associates Board Member 000 0000
Dion Madsen BDC Healthcare Venture Fund Board Member 000 0000
Joseph Oliveto Milestone Pharmaceuticals Chief Executive Officer, President & Board Member 000 0000

5 Former Board Members

You’re viewing 5 of 17 board members. Get the full list »